Parsaclisib Elicits Encouraging Response Rates in Relapsed/Refractory Follicular Lymphoma

Partner | Cancer Centers | <b>SCCA</b>

Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study.

Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase (PI3K)δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study (NCT03126019).1

“In the recommended daily [parsaclisib] dosing group, the objective response rate [ORR] was [nearly] 78%, the median duration of response [DOR] was 14.7 months, and median progression-free survival [PFS] was 15.8 months,” said lead investigator Ryan Lynch, MD, who presented the results during the 2021 ASH Annual Meeting.

Follicular lymphoma is considered incurable with frequent relapses, despite high response rates to first-line therapy, said Lynch, a hematologist/oncologist at University of Washington, Seattle Care Alliance. “Parsaclisib was designed to avoid the hepatotoxicity commonly reported with the early-generation drugs of this class [PI3K inhibitors],” he said.

The ORR by independent review committee was 75.4% in all treated patients and 77.7% among those in the daily-dosing group. The complete response rates were 18% and 19%, respectively. As assessed by the investigator, the ORRs were 74.6% and 75.7%, respectively. “The time to response was rapid, with 74% of objective responses among all treated patients occurring at the first 8-week assessment,” Lynch said.

Some 95% (n = 113/119) of all evaluable patients had regression at target lesions, 86% of whom had a greater than 50% reduction in best percentage change in tumor size from baseline.

In the daily dosing group, the median DOR was 14.7 months (95% CI, 12.0-17.5), and the median PFS was 15.8 months (95% CI, 11.0–not evaluable).

The multicenter, open-label CITADEL-203 study enrolled adults with histologically confirmed relapsed/refractory follicular lymphoma (grade 1, 2, or 3a) who had received at least 2 prior systemic therapies, not including PI3K inhibitors or Bruton’s kinase inhibitors. Patients were allocated 1:1 to parsaclisib at 20 mg once daily for 8 weeks followed by 20 mg once weekly (weekly dosing group), or parsaclisib at 20 mg once daily for 8 weeks followed by 2.5 mg once daily continuously (daily dosing group).

As of the January 15, 2021, cutoff date, 126 patients were enrolled, 103 of whom were in the daily dosing group. Thirty-one percent of patients were still receiving treatment at the time of the data cutoff. The primary reasons for discontinuation were progressive disease in 36.5% of patients and adverse events in 21%. The median duration of parsaclisib treatment was 8.5 months for all treated patients and 8.4 months in patients in the daily dosing group, and the median duration of follow-up was 20.6 months (range, 5.7-34.1) and 17.6 months (95% CI, 5.7-33.1) in the 2 groups, respectively. The median time since follicular lymphoma diagnosis was 6 years. Sixty-one percent of patients were at least 65 years old and 77.5% had stage III/IV disease. Patients received a median of 2 prior therapies (range, 1-8) and 49% were refractory to the most recent therapy.

The most common treatment-emergent adverse events (TEAEs) in all treated patients and the daily dosing group were diarrhea (38% and 44%, respectively), nausea (25% and 24%), cough (22% and 24%), fatigue (18% in both groups), pyrexia (18% and 19%), rash (16% and 14%), neutropenia (14% and 16%, respectively), asthenia (13% and 14%, respectively), and arthralgia (10% and 11%, respectively). The most common grade 3 or higher TEAEs were diarrhea, occurring in 12% of all treated patients and 14% of the daily dosing group, and neutropenia (10% and 11%, respectively).

The most common serious TEAEs were diarrhea (7% in all treated patients and 9% in the daily dosing group) and colitis (6% and 8%, respectively). Two deaths occurred due to TEAEs, which were attributed by the investigator to be related parsaclisib—1 patient with Stevens-Johnson syndrome and 1 with pneumonia.

About half of patients required dose interruption. The most frequently occurring TEAEs that led to dose interruption were diarrhea (18%) and neutropenia (7%). Diarrhea (12%) and rash (3%) were the TEAEs that most often lead to dose reduction, which was necessary in about 20% of patients overall. The most common TEAEs that lead to treatment discontinuation were diarrhea (8%) and colitis (5%).

“Grade 3/4 laboratory abnormalities were seldomly seen,” with the most common being a decrease in neutrophil count in about 15% of patients, Lynch said.

Reference

  1. Lynch RC, Avigdor A, McKinney MS, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: primary analysis from a phase 2 study (CITADEL-203). Presented at: 2021 ASH Annual Meeting; December 11-14, 2021; Atlanta, GA. Abstract 813.